GH Company Profile and Key Details
NASDAQ : GH
Guardant Health
$156.17
-6.75-4.14%
At Close 4:00 PM65.78
B-ESG ScoreESG Rating
Price Chart
Stock Price Today
Guardant Health, Inc. (GH) stock declined over -4.14%, trading at $156.17 on NASDAQ, down from the previous close of $162.92. The stock opened at $159.19, fluctuating between $155.75 and $160.90 in the recent session.
Stock Snapshot
162.92
Prev. Close
20.71B
Market Cap
155.75
Day Low
-60.53
P/E Ratio
-2.58
EPS (TTM)
-2.92
Cash Flow per Share
159.19
Open
132.6M
Number of Shares
160.9
Day High
95.22%
Free Float in %
1.34
Book Value
3.33M
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jul 08, 2026 | 159.29 | 160.90 | 155.75 | 156.17 | 3.33M |
| Jul 07, 2026 | 168.03 | 169.27 | 162.58 | 162.92 | 2.47M |
| Jul 06, 2026 | 174.08 | 174.08 | 165.54 | 168.82 | 2.17M |
| Jul 02, 2026 | 171.96 | 171.99 | 166.74 | 167.98 | 3.44M |
| Jul 01, 2026 | 160.76 | 172.61 | 156.16 | 170.77 | 6.7M |
| Jun 30, 2026 | 151.92 | 152.72 | 148.29 | 150.03 | 3.24M |
| Jun 29, 2026 | 150.00 | 153.95 | 148.46 | 153.74 | 2.72M |
| Jun 26, 2026 | 145.61 | 151.85 | 144.27 | 149.22 | 18.77M |
| Jun 25, 2026 | 137.85 | 145.84 | 137.50 | 142.94 | 2.54M |
| Jun 24, 2026 | 133.17 | 141.07 | 132.60 | 136.96 | 3.84M |
| Jun 23, 2026 | 128.67 | 134.75 | 127.62 | 130.83 | 1.93M |
| Jun 22, 2026 | 131.16 | 132.07 | 125.12 | 128.83 | 1.44M |
| Jun 18, 2026 | 132.48 | 134.00 | 130.19 | 131.78 | 3.4M |
| Jun 17, 2026 | 127.34 | 130.79 | 125.00 | 129.11 | 2.1M |
| Jun 16, 2026 | 130.19 | 133.11 | 126.77 | 127.34 | 2.58M |
| Jun 15, 2026 | 135.00 | 135.00 | 128.53 | 129.82 | 1.65M |
| Jun 12, 2026 | 133.15 | 133.66 | 128.50 | 131.62 | 1.46M |
| Jun 11, 2026 | 132.35 | 133.37 | 128.50 | 130.90 | 1.5M |
| Jun 10, 2026 | 130.00 | 133.31 | 128.46 | 130.70 | 1.8M |
| Jun 09, 2026 | 125.27 | 130.36 | 122.76 | 130.12 | 2.26M |
Contact Details
About Company
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
Company Information
| Employees | 1999 |
| Beta | 1.59 |
| Sales or Revenue | $563.95M |
| 5Y Sales Change% | 0.689% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Diagnostics & Research |
Stock Peers
IDXX
-14.58-2.56%
IDEXX Laboratories, Inc.$555.67MEDP-14.3-2.62%
Medpace Holdings, Inc.$531.99NTRA-6.88-2.45%
Natera, Inc.$274.39ILMN-3.95-2.06%
Illumina, Inc.$187.81ICLR-3.25-1.93%
ICON Public Limited Company$165.47BLLN2.56+2.17%
BillionToOne, Inc.$120.60ILMNV1.75+1.66%
Illumina, Inc. Common Stock Ex-distribution When-Issued$107.00EXAS00
Exact Sciences Corporation$104.91TWST-1.65-1.81%
Twist Bioscience Corporation$89.38RDNT-2.24-3.30%
RadNet, Inc.$65.59Company Overview
Guardant Health, Inc. (NASDAQ:GH) closed at $156.17 USD, losing -$6.75 (-4.14%) from the previous close of $162.92. The stock is currently mid-range between its 52-week high and low $40.35 and $174.08. With a market capitalization of about $20.71 billion, Guardant Health, Inc. is classified as a large-cap and shows higher-than-market volatility (beta ~1.59). Key stats such as the average daily volume over the past year has been around 2.73 million shares, in line with its 52-week average. Headquartered in Palo Alto, CA, Guardant Health, Inc. operates in the Healthcare sector and the Medical - Diagnostics & Research industry. Led by CEO Helmy Eltoukhy, the company employs approximately 2,506 people and listed since October 04, 2018. Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally.
Technical Performance
GH has shown sold momentum, gaining 6.79% over the past week and 75.48% over the past quarter, though year-to-date performance is up 12.46%. Short-term trend indicators are mixed aligned (SMA20 -6.31%, SMA50 -7.5%, SMA200 32.17%). The stock’s 14-day RSI is 40.83 (neutral), while the ATR of 6.14 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -18.86% below its high and over 180.88% above its low. Average 10-day trading volume of 3.44 million shares is slightly above the 3-month average of 2.80 million, indicating heightened recent market interest.
Valuation Metrics
Guardant Health, Inc. trades at a P/E ratio of -46.47, slightly below the S&P 500 average, with a price-to-sales ratio of 19.34 and a price-to-book ratio of -114.21 indicating negative book value, which may reflect financial stress. The P/FCF stands at -92.91, also below market averages.
Dividend & Fair Value
Guardant Health, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$142.04. This means the shares are trading below this model’s fair value.
Earnings & Analyst Outlook
Guardant Health, Inc. generated EPS of -$3.31 over the past year. Five-year average earnings growth is -4.99%. Wall Street analysts project EPS growth of 60.35% annually over the next five years. The latest quarter delivered EPS of -$0.85. The next quarter is forecast at -$0.81. Next year's EPS is expected at $4.46. Analyst sentiment is bullish. Analyst rating data shows there are 34 Strong Buy ratings, 30 Buy ratings, 4 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $215.00 to $60.00. The high target offers 37.67% upside. The low target suggests -61.58% downside. The mean target is $120.51. This offers -22.83% upside. Guardant Health, Inc. earnings surprise history is a mixed track record. The quarter that ended May 07, 2026, missed forecasts by 80.85%. The prior quarter beat by 17.38%. Over the last six quarters, Apple has recorded several small beats. These include -17.33% in February 20, 2025.
Shareholding & Insider Activity
Guardant Health, Inc. has 124.71 million shares outstanding. The public float is 119.56 million shares, elevated short interest at 7.91% of float. This equals 9.40 million shares. The short ratio is 4.22 days. Institutional investors hold 103.78% of the float. Insiders own 4.5%. Eltoukhy Helmy holds 2.01 million shares, Talasaz AmirAli has 1.88 million shares and Freeman Chris has 60.03 thousand shares. Over the past six months, insider transactions show net selling. They sold 212.77 thousand shares across 28 transactions.
Price Forecast & Outlook
Our AI price prediction model suggests that Guardant Health, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 13.76%, with price expected at $177.66 by July 22, 2026, within a range of $167.55 to $187.57 3-Month Outlook: Projected rise of 52.85%, reaching $238.71 by October 06, 2026, with a range of $235.34 to $242.00. 1-Year Outlook: Projected gain of 18.51%, with price at $185.07 by July 08, 2027, within a range of $177.55 to $191.30.
Key Takeaways
Guardant Health, Inc. (NASDAQ:GH) shares are up 12.46% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Guardant Health, Inc. trading at a premium to the broader market with a P/E of -46.47. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $94.42, suggesting -39.54% downside. Our AI forecast model points to short-term strength (13.76% over two weeks), a medium-term rise (52.85% over three months), and a longer-term gain (18.51% over one year), with expected trading ranges indicating moderate volatility.
Frequently Asked Questions
What is the current Guardant Health, Inc. (GH) stock price?
Guardant Health, Inc. (NASDAQ: GH) stock price is $156.17 in the last trading session. During the trading session, GH stock reached the peak price of $160.90 while $155.75 was the lowest point it dropped to. The percentage change in GH stock occurred in the recent session was -4.14% while the dollar amount for the price change in GH stock was - $6.75.
GH's industry and sector of operation?
The NASDAQ listed GH is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector. Guardant Health, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of GH?
Ms. Ines Dahne-Steuber
Chief Operating Officer
Mr. Andy Ament
Senior Vice President of Operations
Dr. Craig Eagle M.D.
Chief Medical Officer
Dr. AmirAli Talasaz Ph.D.
Co-Chief Executive Officer & Director
Ms. Jennifer Higgins
Vice President of Public Affairs
Mr. Kumud Kalia
Chief Information Officer & Chief Operating Officer of Oncology
Mr. Christopher Freeman
Chief Commercial Officer
Dr. Helmy Eltoukhy Ph.D.
Co-Founder, Co-Chief Executive Officer & Chairman
Darya Chudova
Senior Vice President of Technology
Mr. John G. Saia
Chief Legal Officer & Corporation Sec.
Ms. Darya Chudova
Chief Technology Officer
Chief Operating Officer
Mr. Andy Ament
Senior Vice President of Operations
Dr. Craig Eagle M.D.
Chief Medical Officer
Dr. AmirAli Talasaz Ph.D.
Co-Chief Executive Officer & Director
Ms. Jennifer Higgins
Vice President of Public Affairs
Mr. Kumud Kalia
Chief Information Officer & Chief Operating Officer of Oncology
Mr. Christopher Freeman
Chief Commercial Officer
Dr. Helmy Eltoukhy Ph.D.
Co-Founder, Co-Chief Executive Officer & Chairman
Darya Chudova
Senior Vice President of Technology
Mr. John G. Saia
Chief Legal Officer & Corporation Sec.
Ms. Darya Chudova
Chief Technology Officer
How GH did perform over past 52-week?
GH's closing price is 287.04% higher than its 52-week low of $40.35 where as its distance from 52-week high of $174.08 is -10.29%.
How many employees does GH have?
Number of GH employees currently stands at 1,999.
Link for GH official website?
Official Website of GH is: https://guardanthealth.com
How do I contact GH?
GH could be contacted at phone 855 698 8887 and can also be accessed through its website. GH operates from 505 Penobscot Drive, Palo Alto, CA 94063, United States.
How many shares of GH are traded daily?
GH stock volume for the day was 3.33M shares. The average number of GH shares traded daily for last 3 months was 2.73M.
What is the market cap of GH currently?
The market value of GH currently stands at $20.71B with its latest stock price at $156.17 and 132.6M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep